US-China tariff truce offers short-term relief but threatens India's supply chain advantage

In a Geneva conference room over the weekend, negotiators from the United States and China struck a deal that sent relief rippling through global trade circles—and set off alarm bells in New Delhi. The US agreed to slash its tariffs on Chinese goods from 145 percent down to 30 percent. China, in turn, agreed to cut its tariffs on American imports from 125 percent to just 10 percent. The arrangement takes effect Wednesday and lasts for ninety days, a temporary window meant to ease tensions and create space for further talks toward something more permanent.

On the surface, the move looks like a victory for global commerce. A chief economist at a Hong Kong investment firm told Reuters the cuts went further than expected—he had anticipated reductions to around 50 percent—and called it positive news for both countries and the world economy. An Indian trade analyst noted that the agreement effectively reopens a $660 billion trade corridor between Washington and Beijing and provides breathing room for supply chains that have been under severe strain. By rolling back some of the steepest tariffs, companies can resume trading more freely between the two countries.

But beneath this apparent win lies a threat to the very strategy India has been banking on for the past several years. When the Trump administration first imposed heavy tariffs on Chinese goods, Indian policymakers and business leaders saw an opportunity: companies looking to escape Chinese tariffs would diversify their operations, moving production to Vietnam, Mexico, and India. This "China+1" approach was supposed to lock in India's advantage as a manufacturing alternative. Now, as the tariff gap narrows, that advantage evaporates. Companies that relocated production to India might shift operations back to China, where costs are lower and supply chains are mature. The tariff war that was meant to encourage supply chain diversification could end up reversing it entirely.

Industry voices are split on what this means for India's future. The head of India's electronics and semiconductor association warned that the US deals with both the UK and China signal Washington is willing to negotiate generously—but that doesn't guarantee India will keep its position as a favored geography for imports into America's consumer electronics market. The euphoria India felt when Trump's tariffs first took effect, he said, may turn out to be misplaced. Yet he also argued there is no cause for panic: supply chain diversification is a global reality, and India, backed by central government initiatives, will almost certainly capture some of the business fleeing China. An auditing firm's tax partner offered a more cautious assessment: the tariff advantage India held over China on US-bound goods has narrowed, and India must now work harder to stay competitive.

The picture varies by sector. In textiles, an industry convenor saw the truce as timely, coming as India negotiates a trade deal with the US. If India can secure a preferential tariff rate—potentially 10 percent or even zero—it would sharply improve competitiveness in clothing and apparel, placing Indian exporters ahead of Chinese competitors just as global buyers seek to diversify. But an international trade expert countered that if the US significantly lowers tariffs on Chinese goods that overlap with India's export interests, Indian exporters will have a harder time gaining ground in the American market. In medical devices, the differential matters: China now faces 30 percent tariffs while India faces 10 percent, which could motivate companies to move manufacturing from China to India. Yet the decision to relocate depends on weighing potential cost savings—lower labor, cheaper raw materials—against the expense and complexity of actually moving a supply chain.

For pharmaceuticals, the picture is mixed. China is the world's largest manufacturer of active pharmaceutical ingredients and basic chemicals, and the tariff cuts provide relief to the US pharma sector. But for India, the revised tariffs—down from 125 percent to 35 percent—are helpful without being transformative. A former director of India's pharmaceutical export council noted that China's dominance in APIs and chemical precursors means the tariff cuts won't significantly shift the Indian scenario. Meanwhile, the US and China also agreed to crack down on fentanyl trafficking, with the US treasury secretary saying both sides don't want to decouple economically and that China might buy more American goods as negotiations continue.

The ninety-day window is the critical constraint. A professor of Chinese studies at a major Indian university pointed out that the deal lacks detail beyond the tariff numbers themselves, and that China will need time to reach conclusions. The US faces a $1.2 trillion trade deficit and is exploring ways to reduce it, which means China will have to make concessions on that front. When the ninety days expire, tariffs could ratchet back up unless both sides agree to extend the truce. For India, the immediate task is clear: secure preferential trade access with the US, emphasize its role as a reliable alternative sourcing destination, and leverage sectors that remain insulated from US-China trade—pharmaceutical ingredients, gems and jewelry, engineering goods, smartphones, organic chemicals, and IT services. The Make in India and PLI schemes could help hedge against future volatility by attracting companies that want to expand manufacturing capacity outside China. But the window to act is narrow, and the advantage India thought it had locked in is no longer guaranteed.